We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 19, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie (ABBV - Free Report) , Novartis (NVS - Free Report) , Merck (MRK - Free Report) and AstraZeneca (AZN - Free Report) .
Here are highlights from Friday’s Analyst Blog:
4 Large Drug Stocks to Watch as Fundamentals Stay Strong
Investors flocked to the biotech industry during the pandemic years of 2020 and 2021. The successful vaccines and effective antivirals made by the big drugmakers sent the pandemic to the rear-view mirror early his year. However, the post-pandemic trade recovery and strong economic growth have shifted investors’ money to the less expensive sectors. This coupled with a rapid rise in interest rates and inflation has sent biotech valuations plunging recently.
Nonetheless, though biotech industry valuations are currently experiencing a correction, fundamentals remain strong. It is expected that innovation will continue to drive growth in the industry in the second half of 2022 and into 2023. Meanwhile, M&A deals are also picking up, which is a sign of growth. Among the large drugmakers, AbbVie, Novartis, Merck and AstraZeneca are worth retaining in your portfolio.
Industry Description
The Zacks Large Cap Pharmaceuticals industry comprises some of the largest global companies that developmulti-million dollar drugs for a broad range of therapeutic areas like neuroscience, cardiovascular and metabolism, rare diseases, immunology, and oncology. Some of these companies also make vaccines, animal health, medical devices, and consumer-related healthcare products. All these players invest millions of dollars in their product pipelines and line extensions of their already marketed drugs.
Continuous innovation is a defining characteristic of pharma companies and these large drugmakers are constantly investing in drug development and the discovery of new medicines. Regular mergers and acquisitions and collaboration deals are a key feature of large drug companies.
What's Shaping the Future of the Large-Cap Pharma Industry?
Innovation and Pipeline Success: For big drugmakers, innovation in their pipeline is a competitive necessity and key to top-line growth. Pharma companies are constantly striving to ramp up innovation and spending a significantly high portion of their revenues on R&D. Successful innovation and product line extensions in important therapeutic areas and strong clinical study results may act as important catalysts for these stocks.
Aggressive M&A & Collaboration Activity: The sector is characterized by aggressive M&A activity. Given that it takes several years and millions of dollars to develop new therapeutics from scratch, large pharmaceutical companies sitting on huge piles of cash regularly buy innovative small/mid-cap biotech companies to build out their pipelines.
Also, the sloppy sales of mature drugs, dwindling in-house pipelines, government scrutiny of drug prices, and the emergence of big tech firms like Apple and Google in the healthcare industry whet the M&A appetite of large drugmakers.The fast-growing and lucrative markets such as oncology and cell and gene therapy are likely to remain focus areas for M&A activities.
Also, collaborations and partnerships with smaller companies are in full swing. With target valuations dropping to historic lows, big pharma players may use the opportunity for large-scale M&A later this year.
Pipeline Setbacks & Other Headwinds: The failure of key pipeline candidates in pivotal studies and regulatory and pipeline delays can be setbacks for large drug companies and significantly hurt their share prices. Other headwinds for the industry include pricing and competitive pressure, generic competition for blockbuster treatments and a slowdown in sales of some of the most high-profile older drugs.
Uncertainty Surrounding the Pandemic: The pandemic hurt demand trends of physician-administered drugs of most companies. Though trends recovered in 2021, infection rates shot up significantly in the last quarter of 2021, with the rapid spread of the Omicron variant. In 2022 so far, major waves of variants of concern have emerged quickly, become dominant and have been superseded by the next variant. There is still uncertainty about the duration and contemplated impact of the pandemic on companies’ results and outlook in the second half of 2022.
Zacks Industry Rank Indicates Bright Prospects
The Zacks Large Cap Pharmaceuticals industry is a 13-stock group within the broader Medical sector. The group’s Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks.
The Zacks Large Cap Pharmaceuticals industry currently carries a Zacks Industry Rank #99, which places it in the top 40% of more than 250 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.
Before we present a few large drug stocks that are well-positioned to outperform the market based on a strong earnings outlook, let’s take a look at the industry’s performance and its current valuation.
Industry Versus S&P 500 & Sector
The industry has outperformed the S&P 500 as well as the Zacks Medical Sector this year so far.
Stocks in this industry have collectively declined 3.7% this year so far compared with the Zacks S&P 500 composite’s decline of 17.9% and the Zacks Medical Sector’s decline of 20.1% in the said time frame.
Industry's Current Valuation
Based on the forward 12-month price-to-earnings (P/E), a commonly used multiple for valuing large pharma companies, the industry is currently trading at 13.99X compared with the S&P 500’s 16.98X and the Zacks Medical Sector's 20.59X.
Over the last five years, the industry has traded as high as 16.16X, as low as 13.31X and at a median of 14.83X.
4 Large Drugmakers to Keep an Eye On
AbbVie: AbbVie has successfully expanded the labels of its cancer drugs, Imbruvica and Venclexta. It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023. New immunology drugs, Skyrizi and Rinvoq are going strong, bolstered by approval in new indications. AbbVie has several early/mid-stage candidates that have blockbuster potential. Allergan’s acquisition has diversified AbbVie’s revenue base into new therapeutic areas, enhancing its long-term growth potential.
Merck: Merck has a Zacks Rank of 3. The company boasts more than six blockbuster drugs in its portfolio, including the PD-L1 inhibitor, Keytruda, which is approved for several types of cancer and alone accounts for around 40% of its pharmaceutical sales. Keytruda, Gardasil vaccine and Bridion have been driving sales.
Keytruda has played an instrumental role in driving Merck’s revenue growth in the past few years. Keytruda is growing continuously and expanding into new indications and markets globally. With continued label expansion into new indications & early-stage settings, Keytruda is expected to remain a key top-line driver.
Animal health and vaccine products are core growth drivers. Merck’s new COVID oral antiviral pill, Lagevrio has been a key top-line driver in 2022. Merck boasts a strong cancer pipeline, including Keytruda, which should help drive long-term growth.
Shares of Merck have risen 13.2% in the past year. The Zacks Consensus Estimate for 2022 EPS has risen from $7.32 to $7.33 over the past 30 days.
Novartis: Novartis has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug, Cosentyx, a cardiovascular drug, Entresto, gene therapy, Zolgensma, the oncology portfolio, and the launch of Kesimpta continue to boost performance. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also boost performance further.
The pipeline progress is also impressive and the company has some promising candidates. Management’s focus on cost savings should boost the bottom line as well. Management recently decided to separate its generics business, Sandoz into a separate company to focus on its core pharma business.
The Zacks Consensus Estimate for 2022 EPS has remained stable at $6.06 per share over the past 30 days. Novartis is a #3 Ranked stock. This Swiss drugmaker’s stock has declined 7.7% this year so far.
AstraZeneca: AstraZeneca’s key drugs, mainly cancer medicines, Lynparza, Tagrisso and Imfinzi should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets. Cost-cutting efforts should drive earnings. The Alexion buyout strengthens its immunology franchise, adding several drugs that can boost its top line
AstraZeneca has a Zacks Rank #3. The Zacks Consensus Estimate for this British drugmaker’s 2022 EPS has remained stable at $3.31 over the past 30 days. The stock has declined 0.2% this year so far.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca
For Immediate Release
Chicago, IL – September 19, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie (ABBV - Free Report) , Novartis (NVS - Free Report) , Merck (MRK - Free Report) and AstraZeneca (AZN - Free Report) .
Here are highlights from Friday’s Analyst Blog:
4 Large Drug Stocks to Watch as Fundamentals Stay Strong
Investors flocked to the biotech industry during the pandemic years of 2020 and 2021. The successful vaccines and effective antivirals made by the big drugmakers sent the pandemic to the rear-view mirror early his year. However, the post-pandemic trade recovery and strong economic growth have shifted investors’ money to the less expensive sectors. This coupled with a rapid rise in interest rates and inflation has sent biotech valuations plunging recently.
Nonetheless, though biotech industry valuations are currently experiencing a correction, fundamentals remain strong. It is expected that innovation will continue to drive growth in the industry in the second half of 2022 and into 2023. Meanwhile, M&A deals are also picking up, which is a sign of growth. Among the large drugmakers, AbbVie, Novartis, Merck and AstraZeneca are worth retaining in your portfolio.
Industry Description
The Zacks Large Cap Pharmaceuticals industry comprises some of the largest global companies that developmulti-million dollar drugs for a broad range of therapeutic areas like neuroscience, cardiovascular and metabolism, rare diseases, immunology, and oncology. Some of these companies also make vaccines, animal health, medical devices, and consumer-related healthcare products. All these players invest millions of dollars in their product pipelines and line extensions of their already marketed drugs.
Continuous innovation is a defining characteristic of pharma companies and these large drugmakers are constantly investing in drug development and the discovery of new medicines. Regular mergers and acquisitions and collaboration deals are a key feature of large drug companies.
What's Shaping the Future of the Large-Cap Pharma Industry?
Innovation and Pipeline Success: For big drugmakers, innovation in their pipeline is a competitive necessity and key to top-line growth. Pharma companies are constantly striving to ramp up innovation and spending a significantly high portion of their revenues on R&D. Successful innovation and product line extensions in important therapeutic areas and strong clinical study results may act as important catalysts for these stocks.
Aggressive M&A & Collaboration Activity: The sector is characterized by aggressive M&A activity. Given that it takes several years and millions of dollars to develop new therapeutics from scratch, large pharmaceutical companies sitting on huge piles of cash regularly buy innovative small/mid-cap biotech companies to build out their pipelines.
Also, the sloppy sales of mature drugs, dwindling in-house pipelines, government scrutiny of drug prices, and the emergence of big tech firms like Apple and Google in the healthcare industry whet the M&A appetite of large drugmakers.The fast-growing and lucrative markets such as oncology and cell and gene therapy are likely to remain focus areas for M&A activities.
Also, collaborations and partnerships with smaller companies are in full swing. With target valuations dropping to historic lows, big pharma players may use the opportunity for large-scale M&A later this year.
Pipeline Setbacks & Other Headwinds: The failure of key pipeline candidates in pivotal studies and regulatory and pipeline delays can be setbacks for large drug companies and significantly hurt their share prices. Other headwinds for the industry include pricing and competitive pressure, generic competition for blockbuster treatments and a slowdown in sales of some of the most high-profile older drugs.
Uncertainty Surrounding the Pandemic: The pandemic hurt demand trends of physician-administered drugs of most companies. Though trends recovered in 2021, infection rates shot up significantly in the last quarter of 2021, with the rapid spread of the Omicron variant. In 2022 so far, major waves of variants of concern have emerged quickly, become dominant and have been superseded by the next variant. There is still uncertainty about the duration and contemplated impact of the pandemic on companies’ results and outlook in the second half of 2022.
Zacks Industry Rank Indicates Bright Prospects
The Zacks Large Cap Pharmaceuticals industry is a 13-stock group within the broader Medical sector. The group’s Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks.
The Zacks Large Cap Pharmaceuticals industry currently carries a Zacks Industry Rank #99, which places it in the top 40% of more than 250 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.
Before we present a few large drug stocks that are well-positioned to outperform the market based on a strong earnings outlook, let’s take a look at the industry’s performance and its current valuation.
Industry Versus S&P 500 & Sector
The industry has outperformed the S&P 500 as well as the Zacks Medical Sector this year so far.
Stocks in this industry have collectively declined 3.7% this year so far compared with the Zacks S&P 500 composite’s decline of 17.9% and the Zacks Medical Sector’s decline of 20.1% in the said time frame.
Industry's Current Valuation
Based on the forward 12-month price-to-earnings (P/E), a commonly used multiple for valuing large pharma companies, the industry is currently trading at 13.99X compared with the S&P 500’s 16.98X and the Zacks Medical Sector's 20.59X.
Over the last five years, the industry has traded as high as 16.16X, as low as 13.31X and at a median of 14.83X.
4 Large Drugmakers to Keep an Eye On
AbbVie: AbbVie has successfully expanded the labels of its cancer drugs, Imbruvica and Venclexta. It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023. New immunology drugs, Skyrizi and Rinvoq are going strong, bolstered by approval in new indications. AbbVie has several early/mid-stage candidates that have blockbuster potential. Allergan’s acquisition has diversified AbbVie’s revenue base into new therapeutic areas, enhancing its long-term growth potential.
AbbVie has a Zacks Rank #3 (Hold). The Zacks Consensus Estimate for 2022 EPS has remained stable at $13.90 per share over the past 30 days. The stock has risen 5.2% this year so far. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merck: Merck has a Zacks Rank of 3. The company boasts more than six blockbuster drugs in its portfolio, including the PD-L1 inhibitor, Keytruda, which is approved for several types of cancer and alone accounts for around 40% of its pharmaceutical sales. Keytruda, Gardasil vaccine and Bridion have been driving sales.
Keytruda has played an instrumental role in driving Merck’s revenue growth in the past few years. Keytruda is growing continuously and expanding into new indications and markets globally. With continued label expansion into new indications & early-stage settings, Keytruda is expected to remain a key top-line driver.
Animal health and vaccine products are core growth drivers. Merck’s new COVID oral antiviral pill, Lagevrio has been a key top-line driver in 2022. Merck boasts a strong cancer pipeline, including Keytruda, which should help drive long-term growth.
Shares of Merck have risen 13.2% in the past year. The Zacks Consensus Estimate for 2022 EPS has risen from $7.32 to $7.33 over the past 30 days.
Novartis: Novartis has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug, Cosentyx, a cardiovascular drug, Entresto, gene therapy, Zolgensma, the oncology portfolio, and the launch of Kesimpta continue to boost performance. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also boost performance further.
The pipeline progress is also impressive and the company has some promising candidates. Management’s focus on cost savings should boost the bottom line as well. Management recently decided to separate its generics business, Sandoz into a separate company to focus on its core pharma business.
The Zacks Consensus Estimate for 2022 EPS has remained stable at $6.06 per share over the past 30 days. Novartis is a #3 Ranked stock. This Swiss drugmaker’s stock has declined 7.7% this year so far.
AstraZeneca: AstraZeneca’s key drugs, mainly cancer medicines, Lynparza, Tagrisso and Imfinzi should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets. Cost-cutting efforts should drive earnings. The Alexion buyout strengthens its immunology franchise, adding several drugs that can boost its top line
AstraZeneca has a Zacks Rank #3. The Zacks Consensus Estimate for this British drugmaker’s 2022 EPS has remained stable at $3.31 over the past 30 days. The stock has declined 0.2% this year so far.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.